Maa: Etelä-Afrikka
Kieli: englanti
Lähde: South African Health Products Regulatory Authority (SAHPRA)
Aspen-p
RIDAQ-12,5 (tablet) SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): RIDAQ-12,5 (tablet) COMPOSITION: Each tablet contains: 12,5 mg Hydrochlorothiazide PHARMACOLOGICAL CLASSIFICATION: A 18.1 Diuretics PHARMACOLOGICAL ACTION: Hydrochlorothiazide is a diuretic which reduces the reabsorption of electrolytes from the renal tubules, thereby increasing the excretion of sodium, potassium and chloride ions, and consequently of water. It also slightly increases bicarbonate excretion without appreciable alteration of the acid-base balance or the pH of the urine. It has a lowering effect on the blood pressure and enhances the action of other hypotensives agents such as guanethidine, methyldopa and rauwolfi alkaloids. Pharmacokinetics Hydrochlorothiazide is absorbed from the gastro-intestinal tract, distributed throughout the extracellular space and diffuses across the placenta. Diuresis occurs in about two hours, reaches a maximum in about four hours, and lasts for about twelve hours. Tolerance does not develop and therapeutic efficacy is maintained when it is administered over long periods, but patients may not respond if their glomerular filtration-rate is markedly reduced. The route of elimination is via the kidneys. INDICATIONS: Mild to moderate hypertension alone or in combination with other anti-hypertensives. CONTRA-INDICATIONS: RIDAQ-12,5 is contra-indicated in patients with: • A known hypersensitivity to hydrochlorothiazide • Severe renal and/or hepatic insufficiency • Addison’s disease • Pre-existing hypercalcaemia WARNINGS: See “ SPECIAL PRECAUTIONS” INTERACTIONS: • RIDAQ-12,5 may enhance the toxicity of digitalis glycosides by depleting serum potassium concentrations. • It may enhance the neuromuscular blocking action of competitive muscle relaxants, Lue koko asiakirja